

Amendments to the Specification:

Please amend the specification as-filed as follows:

Please delete paragraph [0009] and replace it with the following paragraph:

[0009] Accordingly, the present invention provides the following:

[1] A humanized antibody binding to CD47.

[2] The humanized antibody as defined in [1] above, wherein CD47 is human CD47.

[3] The humanized antibody as defined in [1] or [2] above, wherein the CDRs of the humanized antibody are derived from a mouse antibody.

[4] The humanized antibody as defined in any one of [1] to [3] above, comprising any one of the sequence sets below:

(1) the sequence of aa 31-35 (CDR1), the sequence of aa 50-66 (CDR2), and the sequence of aa 99-106 (CDR3) of SEQ ID NO: [[7]]93;

(2) the sequence of aa 31-35 (CDR1), the sequence of aa 50-66 (CDR2), and the sequence of aa 99-106 (CDR3) of SEQ ID NO: [[10]]94;

(3) the sequence of aa 31-35 (CDR1), the sequence of aa 50-66 (CDR2), and the sequence of aa 99-106 (CDR3) of SEQ ID NO: [[13]]95;

(4) the sequence of aa 31-35 (CDR1), the sequence of aa 50-66 (CDR2), and the sequence of aa 99-106 (CDR3) of SEQ ID NO: [[16]]96;

(5) the sequence of aa 31-35 (CDR1), the sequence of aa 50-66 (CDR2), and the sequence of aa 99-106 (CDR3) of SEQ ID NO: [[19]]97;

(6) the sequence of aa 31-35 (CDR1), the sequence of aa 50-66 (CDR2), and the sequence of aa 99-106 (CDR3) of SEQ ID NO: [[22]]98;

(7) the sequence of aa 31-35 (CDR1), the sequence of aa 50-66 (CDR2), and the sequence of aa 99-106 (CDR3) of SEQ ID NO: [[30]]99;

(8) the sequence of aa 24-39 (CDR1), the sequence of aa 55-61 (CDR2), and the sequence of aa 94-102 (CDR3) of SEQ ID NO: [[37]]100;

(9) the sequence of aa 24-39 (CDR1), the sequence of aa 55-61 (CDR2), and the sequence of aa 94-102 (CDR3) of SEQ ID NO: [[40]]101;

(10) the sequence of aa 24-39 (CDR1), the sequence of aa 55-61 (CDR2), and the

sequence of aa 94-102 (CDR3) of SEQ ID NO: [[43]]102;

(11) the sequence of aa 24-39 (CDR1), the sequence of aa 55-61 (CDR2), and the sequence of aa 94-102 (CDR3) of SEQ ID NO: [[46]]103;

(12) the sequence of aa 24-39 (CDR1), the sequence of aa 55-61 (CDR2), and the sequence of aa 94-102 (CDR3) of SEQ ID NO: [[49]]104;

(13) the sequence of aa 24-39 (CDR1), the sequence of aa 55-61 (CDR2), and the sequence of aa 94-102 (CDR3) of SEQ ID NO: [[52]]105;

(14) the sequence of aa 24-39 (CDR1), the sequence of aa 55-61 (CDR2), and the sequence of aa 94-102 (CDR3) of SEQ ID NO: [[57]]106;

(15) the sequence of aa 31-35 (CDR1), the sequence of aa 50-66 (CDR2), and the sequence of aa 99-106 (CDR3) of SEQ ID NO: [[64]]107; and

(16) the sequence of aa 24-39 (CDR1), the sequence of aa 55-61 (CDR2), and the sequence of aa 94-102 (CDR3) of SEQ ID NO: [[67]]108.

[5] The humanized antibody as defined in any one of [1] to [3] above, comprising any one of the sequence sets below:

(1) the sequence of aa 1-30 (FR1), the sequence of aa 36-49 (FR2), the sequence of aa 67-98 (FR3), and the sequence of aa 107-117 (FR4) of SEQ ID NO: [[7]]93;

(2) the sequence of aa 1-30 (FR1), the sequence of aa 36-49 (FR2), the sequence of aa 67-98 (FR3), and the sequence of aa 107-117 (FR4) of SEQ ID NO: [[10]]94;

(3) the sequence of aa 1-30 (FR1), the sequence of aa 36-49 (FR2), the sequence of aa 67-98 (FR3), and the sequence of aa 107-117 (FR4) of SEQ ID NO: [[13]]95;

(4) the sequence of aa 1-30 (FR1), the sequence of aa 36-49 (FR2), the sequence of aa 67-98 (FR3), and the sequence of aa 107-117 (FR4) of SEQ ID NO: [[16]]96;

(5) the sequence of aa 1-30 (FR1), the sequence of aa 36-49 (FR2), the sequence of aa 67-98 (FR3), and the sequence of aa 107-117 (FR4) of SEQ ID NO: [[19]]97;

(6) the sequence of aa 1-30 (FR1), the sequence of aa 36-49 (FR2), the sequence of aa 67-98 (FR3), and the sequence of aa 107-117 (FR4) of SEQ ID NO: [[22]]98;

(7) the sequence of aa 1-30 (FR1), the sequence of aa 36-49 (FR2), the sequence of aa 67-98 (FR3), and the sequence of aa 107-117 (FR4) of SEQ ID NO: [[30]]99;

(8) the sequence of aa 1-23 (FR1), the sequence of aa 40-54 (FR2), the sequence of aa 62-93 (FR3), and the sequence of aa 103-112 (FR4) of SEQ ID NO: [[37]]100;

(9) the sequence of aa 1-23 (FR1), the sequence of aa 40-54 (FR2), the sequence of aa 62-93 (FR3), and the sequence of aa 103-112 (FR4) of SEQ ID NO: [[40]]101;

(10) the sequence of aa 1-23 (FR1), the sequence of aa 40-54 (FR2), the sequence of aa 62-93 (FR3), and the sequence of aa 103-112 (FR4) of SEQ ID NO: [[43]]102;

(11) the sequence of aa 1-23 (FR1), the sequence of aa 40-54 (FR2), the sequence of aa 62-93 (FR3), and the sequence of aa 103-112 (FR4) of SEQ ID NO: [[46]]103;

(12) the sequence of aa 1-23 (FR1), the sequence of aa 40-54 (FR2), the sequence of aa 62-93 (FR3), and the sequence of aa 103-112 (FR4) of SEQ ID NO: [[49]]104;

(13) the sequence of aa 1-23 (FR1), the sequence of aa 40-54 (FR2), the sequence of aa 62-93 (FR3), and the sequence of aa 103-112 (FR4) of SEQ ID NO: [[52]]105;

(14) the sequence of aa 1-23 (FR1), the sequence of aa 40-54 (FR2), the sequence of aa 62-93 (FR3), and the sequence of aa 103-112 (FR4) of SEQ ID NO: [[57]]106;

(15) the sequence of aa 1-30 (FR1), the sequence of aa 36-49 (FR2), the sequence of aa 67-98 (FR3), and the sequence of aa 107-117 (FR4) of SEQ ID NO: [[64]]107; and

(16) the sequence of aa 1-23 (FR1), the sequence of aa 40-54 (FR2), the sequence of aa 62-93 (FR3), and the sequence of aa 103-112 (FR4) of SEQ ID NO: [[67]]108.

[6] The humanized antibody as defined in any one of [1]-[5] above, which is a small antibody fragment.

[7] The humanized antibody as defined in [6] above, which is a diabody.

[8] The humanized antibody as defined in [7] above, which is a single-chain diabody.

[9] The humanized antibody as defined in [7] or [8] above, characterized in that a disulfide bond exists between diabody-forming fragments.

[10] The humanized antibody as defined in [9] above characterized by:

(1) an antibody having the amino acid sequence of SEQ ID NO: 90; or

(2) an antibody having an amino acid sequence containing a deletion, addition or substitution of one or several amino acid(s) in the amino acid sequence of (1) and having CD47-binding activity.

[11] The humanized antibody as defined in [9] above characterized by:

(1) an antibody having the amino acid sequence of SEQ ID NO: 92; or

(2) an antibody having an amino acid sequence containing a deletion, addition or substitution of one or several amino acid(s) in the amino acid sequence of (1) and having

CD47-binding activity.

[12] A diabody antibody binding to human CD47, characterized in that a disulfide bond exists between diabody-forming fragments.

[13] The diabody antibody as defined in [12] above comprising any one of the sequence sets below:

(1) the sequence of aa 31-35 (CDR1), the sequence of aa 50-66 (CDR2), and the sequence of aa 99-106 (CDR3) of SEQ ID NO: [[7]]93;

(2) the sequence of aa 31-35 (CDR1), the sequence of aa 50-66 (CDR2), and the sequence of aa 99-106 (CDR3) of SEQ ID NO: [[10]]94;

(3) the sequence of aa 31-35 (CDR1), the sequence of aa 50-66 (CDR2), and the sequence of aa 99-106 (CDR3) of SEQ ID NO: [[13]]95;

(4) the sequence of aa 31-35 (CDR1), the sequence of aa 50-66 (CDR2), and the sequence of aa 99-106 (CDR3) of SEQ ID NO: [[16]]96;

(5) the sequence of aa 31-35 (CDR1), the sequence of aa 50-66 (CDR2), and the sequence of aa 99-106 (CDR3) of SEQ ID NO: [[19]]97;

(6) the sequence of aa 31-35 (CDR1), the sequence of aa 50-66 (CDR2), and the sequence of aa 99-106 (CDR3) of SEQ ID NO: [[22]]98;

(7) the sequence of aa 31-35 (CDR1), the sequence of aa 50-66 (CDR2), and the sequence of aa 99-106 (CDR3) of SEQ ID NO: [[30]]99;

(8) the sequence of aa 24-39 (CDR1), the sequence of aa 55-61 (CDR2), and the sequence of aa 94-102 (CDR3) of SEQ ID NO: [[37]]100;

(9) the sequence of aa 24-39 (CDR1), the sequence of aa 55-61 (CDR2), and the sequence of aa 94-102 (CDR3) of SEQ ID NO: [[40]]101;

(10) the sequence of aa 24-39 (CDR1), the sequence of aa 55-61 (CDR2), and the sequence of aa 94-102 (CDR3) of SEQ ID NO: [[43]]102;

(11) the sequence of aa 24-39 (CDR1), the sequence of aa 55-61 (CDR2), and the sequence of aa 94-102 (CDR3) of SEQ ID NO: [[46]]103;

(12) the sequence of aa 24-39 (CDR1), the sequence of aa 55-61 (CDR2), and the sequence of aa 94-102 (CDR3) of SEQ ID NO: [[49]]104;

(13) the sequence of aa 24-39 (CDR1), the sequence of aa 55-61 (CDR2), and the sequence of aa 94-102 (CDR3) of SEQ ID NO: [[52]]105;

(14) the sequence of aa 24-39 (CDR1), the sequence of aa 55-61 (CDR2), and the sequence of aa 94-102 (CDR3) of SEQ ID NO: [[57]]106;

(15) the sequence of aa 31-35 (CDR1), the sequence of aa 50-66 (CDR2), and the sequence of aa 99-106 (CDR3) of SEQ ID NO: [[64]]107; and

(16) the sequence of aa 24-39 (CDR1), the sequence of aa 55-61 (CDR2), and the sequence of aa 94-102 (CDR3) of SEQ ID NO: [[67]]108.

[14] A humanized antibody binding to CD47 comprising:

(1) a heavy chain variable region containing the sequence of aa 1-117 of SEQ ID NO: [[30]]99; and

(2) a light chain variable region containing the sequence of aa 1-112 of SEQ ID NO: [[57]]106.

[15] A humanized antibody binding to CD47 comprising:

(1) a heavy chain variable region containing the sequence of aa 1-117 of SEQ ID NO: [[64]]107; and

(2) a light chain variable region containing the sequence of aa 1-112 of SEQ ID NO: [[67]]108.

[16] An antibody binding to CD47 comprising any one of:

(1) the sequence of aa 1-234 of SEQ ID NO: [[73]]110;

(2) the sequence of aa 1-234 of SEQ ID NO: [[74]]111;

(3) the sequence of aa 1-483 of SEQ ID NO: [[78]]113; and

(4) the sequence of aa 1-483 of SEQ ID NO: [[79]]114.

[17] A gene encoding the antibody as defined in any one of [1]-[16] above.

[18] A vector containing the gene as defined in [17] above.

[19] A host cell containing the vector as defined in [18] above.

[20] A process for preparing an antibody, comprising the step of culturing the host cell as defined in [19] above.

[21] A therapeutic agent for hematological disorder, comprising the antibody as defined in any one of [1]-[16] above.

[22] The therapeutic agent as defined in [21] above, wherein the hematological disorder is selected from leukemias such as acute myelocytic leukemia, chronic myelocytic leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, adult T-cell leukemia,

multiple myeloma, mixed leukemia, and hairy cell leukemia; malignant lymphoma (Hodgkin's disease, non-Hodgkin's lymphoma), aplastic anemia, myelodysplastic syndromes, and polycythemia vera.

BRIEF DESCRIPTION OF THE DRAWINGS

Please delete paragraphs [0023] to [0024] and replace them with the following paragraphs:

[0023] The amino acid sequences of the CDRs and FRs of humanized anti-CD47 antibodies of the present invention are not specifically limited so far as CD47-binding activity is retained, and any sequence can be used. The CDRs preferably have any one of the amino acid sequence sets below:

(1) the sequence of aa 31-35 (CDR1), the sequence of aa 50-66 (CDR2), and the sequence of aa 99-106 (CDR3) of SEQ ID NO: [[7]]93;

(2) the sequence of aa 31-35 (CDR1), the sequence of aa 50-66 (CDR2), and the sequence of aa 99-106 (CDR3) of SEQ ID NO: [[10]]94;

(3) the sequence of aa 31-35 (CDR1), the sequence of aa 50-66 (CDR2), and the sequence of aa 99-106 (CDR3) of SEQ ID NO: [[13]]95;

(4) the sequence of aa 31-35 (CDR1), the sequence of aa 50-66 (CDR2), and the sequence of aa 99-106 (CDR3) of SEQ ID NO: [[16]]96;

(5) the sequence of aa 31-35 (CDR1), the sequence of aa 50-66 (CDR2), and the sequence of aa 99-106 (CDR3) of SEQ ID NO: [[19]]97;

(6) the sequence of aa 31-35 (CDR1), the sequence of aa 50-66 (CDR2), and the sequence of aa 99-106 (CDR3) of SEQ ID NO: [[22]]98;

(7) the sequence of aa 31-35 (CDR1), the sequence of aa 50-66 (CDR2), and the sequence of aa 99-106 (CDR3) of SEQ ID NO: [[30]]99;

(8) the sequence of aa 24-39 (CDR1), the sequence of aa 55-61 (CDR2), and the sequence of aa 94-102 (CDR3) of SEQ ID NO: [[37]]100;

(9) the sequence of aa 24-39 (CDR1), the sequence of aa 55-61 (CDR2), and the sequence of aa 94-102 (CDR3) of SEQ ID NO: [[40]]101;

(10) the sequence of aa 24-39 (CDR1), the sequence of aa 55-61 (CDR2), and the

sequence of aa 94-102 (CDR3) of SEQ ID NO: [[43]]102;

(11) the sequence of aa 24-39 (CDR1), the sequence of aa 55-61 (CDR2), and the sequence of aa 94-102 (CDR3) of SEQ ID NO: [[46]]103;

(12) the sequence of aa 24-39 (CDR1), the sequence of aa 55-61 (CDR2), and the sequence of aa 94-102 (CDR3) of SEQ ID NO: [[49]]104;

(13) the sequence of aa 24-39 (CDR1), the sequence of aa 55-61 (CDR2), and the sequence of aa 94-102 (CDR3) of SEQ ID NO: [[52]]105;

(14) the sequence of aa 24-39 (CDR1), the sequence of aa 55-61 (CDR2), and the sequence of aa 94-102 (CDR3) of SEQ ID NO: [[57]]106;

(15) the sequence of aa 31-35 (CDR1), the sequence of aa 50-66 (CDR2), and the sequence of aa 99-106 (CDR3) of SEQ ID NO: [[64]]107; and

(16) the sequence of aa 24-39 (CDR1), the sequence of aa 55-61 (CDR2), and the sequence of aa 94-102 (CDR3) of SEQ ID NO: [[67]]108.

[0024] The FRs preferably have any one of the amino acid sequence sets below:

(1) the sequence of aa 1-30 (FR1), the sequence of aa 36-49 (FR2), the sequence of aa 67-98 (FR3), and the sequence of aa 107-117 (FR4) of SEQ ID NO: [[7]]93;

(2) the sequence of aa 1-30 (FR1), the sequence of aa 36-49 (FR2), the sequence of aa 67-98 (FR3), and the sequence of aa 107-117 (FR4) of SEQ ID NO: [[10]]94;

(3) the sequence of aa 1-30 (FR1), the sequence of aa 36-49 (FR2), the sequence of aa 67-98 (FR3), and the sequence of aa 107-117 (FR4) of SEQ ID NO: [[13]]95;

(4) the sequence of aa 1-30 (FR1), the sequence of aa 36-49 (FR2), the sequence of aa 67-98 (FR3), and the sequence of aa 107-117 (FR4) of SEQ ID NO: [[16]]96;

(5) the sequence of aa 1-30 (FR1), the sequence of aa 36-49 (FR2), the sequence of aa 67-98 (FR3), and the sequence of aa 107-117 (FR4) of SEQ ID NO: [[19]]97;

(6) the sequence of aa 1-30 (FR1), the sequence of aa 36-49 (FR2), the sequence of aa 67-98 (FR3), and the sequence of aa 107-117 (FR4) of SEQ ID NO: [[22]]98;

(7) the sequence of aa 1-30 (FR1), the sequence of aa 36-49 (FR2), the sequence of aa 67-98 (FR3), and the sequence of aa 107-117 (FR4) of SEQ ID NO: [[30]]99;

(8) the sequence of aa 1-23 (FR1), the sequence of aa 40-54 (FR2), the sequence of aa 62-93 (FR3), and the sequence of aa 103-112 (FR4) of SEQ ID NO: [[37]]100;

(9) the sequence of aa 1-23 (FR1), the sequence of aa 40-54 (FR2), the sequence of aa

62-93 (FR3), and the sequence of aa 103-112 (FR4) of SEQ ID NO: [[40]]101;

(10) the sequence of aa 1-23 (FR1), the sequence of aa 40-54 (FR2), the sequence of aa 62-93 (FR3), and the sequence of aa 103-112 (FR4) of SEQ ID NO: [[43]]102;

(11) the sequence of aa 1-23 (FR1), the sequence of aa 40-54 (FR2), the sequence of aa 62-93 (FR3), and the sequence of aa 103-112 (FR4) of SEQ ID NO: [[46]]103;

(12) the sequence of aa 1-23 (FR1), the sequence of aa 40-54 (FR2), the sequence of aa 62-93 (FR3), and the sequence of aa 103-112 (FR4) of SEQ ID NO: [[49]]104;

(13) the sequence of aa 1-23 (FR1), the sequence of aa 40-54 (FR2), the sequence of aa 62-93 (FR3), and the sequence of aa 103-112 (FR4) of SEQ ID NO: [[52]]105;

(14) the sequence of aa 1-23 (FR1), the sequence of aa 40-54 (FR2), the sequence of aa 62-93 (FR3), and the sequence of aa 103-112 (FR4) of SEQ ID NO: [[57]]106;

(15) the sequence of aa 1-30 (FR1), the sequence of aa 36-49 (FR2), the sequence of aa 67-98 (FR3), and the sequence of aa 107-117 (FR4) of SEQ ID NO: [[64]]107; and

(16) the sequence of aa 1-23 (FR1), the sequence of aa 40-54 (FR2), the sequence of aa 62-93 (FR3), and the sequence of aa 103-112 (FR4) of SEQ ID NO: [[67]]108.

Preparation of anti-CD47 antibodies and CDR sequences

Please delete paragraph [0100] and replace it with the following paragraph:

[0100] (ii) Secondary design

Considering the conservation of the sequence WYLQ-PGQSP—LIY (SEQ ID NO: 122) of FR2, homology searches were performed again for the humanized MABL-2 antibody L chains. As a result, the human antibody 1802359A showing the highest homology (Pascual V. et al., J. Immunol., 146(12), 4385-4391, 1991) was selected to use the FRs therefrom. In humanized huM2 antibody L chain version "2.1", FR1-FR4 were identical with FR1-FR4 of the human antibody 1802359A, and the CDRs were identical with the CDRs in the L chain V region of the mouse MABL-2 antibody. For lack of information of the leader sequence of 1802359A, the leader sequence of the human antibody HSJC11VJ used in the primary design was used.

Please delete paragraphs [0131] to [0132] and replace them with the following paragraphs:

[0131] The PCR products A-B (huM2Db-1) and C-D (huM2Db-2) were separated by electrophoresis on a 1.2% agarose gel and purified, and assembled in second PCR. In the second PCR, 100 µL of a reaction mixture containing 1 µL of huM2Db-1 and 1 µL of huM2Db-2 as templates and 2 U KOD -Plus- was incubated for 5 cycles of 94°C for 15 seconds, 50°C for 30 seconds, and 68°C for 1 minute, followed by incubation at 68°C for 5 minutes, and then 40 pmol each of the PCR primers were added. Subsequently, 35 rounds of PCR were performed under the same conditions as those of the first PCR, and the PCR product was purified using QIAquick PCR Purification Kit (QIAGEN), and digested with SalI and NotI, and the resulting DNA fragment was cloned into the vector pCHO1-Igs (WO00/53634). This expression vector pCHO1-Igs contains a mouse IgG1 signal sequence suitable for mammal secretory cell expression systems (Nature, 332, 323-327, 1988). After DNA sequencing, a plasmid containing a DNA fragment encoding the correct amino acid sequence of the humanized MABL-2 antibody HL5 was designated pCHOhuM2Db. The nucleotide sequence and amino acid sequence of the humanized MABL-2 antibody HL5 contained in this plasmid pCHOhuM2Db are shown in SEQ ID [[NØ:]] **NOS: 73 and 110, respectively.**

[0132] (2) Preparation of a humanized MABL-1 antibody single-chain Fv (HL5)
A humanized MABL-1 antibody HL5 was prepared in the same manner as described for the preparation of the humanized MABL-2 antibody single-chain Fv (HL5) above. In the first PCR, the plasmid HEF-huM1H2.1#1 encoding the humanized MABL-1 antibody H chain V region (see Example 2) was used in place of HEF-huM2H2.1#3, and the plasmid HEF-huM1L2.1#1 encoding the humanized MABL-1 antibody L chain V region (see Example 2) was used in place of HEF-huM2L2.1#1 to give PCR products huM1Db-1 and huM1Db-2. The second PCR using them gave a plasmid pCHOhuM1Db containing a DNA fragment encoding the correct amino acid sequence of the humanized MABL-1 antibody HL5. The nucleotide sequence and amino acid sequence of the humanized MABL-1 antibody HL5 contained in this plasmid pCHOhuM1Db are shown in SEQ ID [[NØ:]] **NOS: 74 and 111,**

respectively.

Please delete paragraph [0137] and replace it with the following paragraph:

[0137] The PCR products C-F (huM2Db-3) and E-B (huM2Db-4) were separated by electrophoresis on a 1.2% agarose gel and purified, and used for assembling with huM2Db-1 and huM2Db-2 in the second PCR. In the second PCR, 100 µL of a reaction mixture containing 1 µL each of huM2Db-1 and huM2Db-3 or 1 µL each of huM2Db-2 and huM2Db-4 as templates and 2 U KOD -Plus- was incubated for 5 cycles of 94°C for 15 seconds, 50°C for 30 seconds, and 68°C for 1 minute, followed by incubation at 68°C for 5 minutes, and then 40 pmol each of the PCR primers were added. Subsequently, 35 rounds of PCR were performed under the same conditions as those of the first PCR, and the PCR products were purified using QIAquick PCR Purification Kit (QIAGEN), and huM2Db-13 was digested with SalI and BamHI and huM2Db-24 was digested with BamHI and NotI, and the resulting DNA fragments were cloned into the pCHO1-Igs vector. After DNA sequencing, a plasmid containing a DNA fragment encoding the correct amino acid sequence of the humanized MABL-2 antibody sc(Fv)2 was designated pCHOhuM2scDb. The nucleotide sequence and amino acid sequence of the humanized MABL-2 antibody sc(Fv)2 contained in this plasmid pCHOhuM2scDb are shown in SEQ ID [[NØ:]] **NOS: 78 and 113, respectively.**

Please delete paragraph [0139] and replace it with the following paragraph:

[0139] In the first PCR, the PCR product huM1Db-2 encoding the humanized MABL-1 antibody L chain V region was used in place of the PCR product huM2Db-2, and the PCR product huM1Db-1 encoding the humanized MABL-1 antibody H chain V region was used in place of the PCR product huM2Db-1 to give a plasmid pCHOhuM1scDb containing a DNA fragment encoding the correct amino acid sequence of the humanized MABL-1 antibody sc(Fv)2. The nucleotide sequence and amino acid sequence of the humanized MABL-1 antibody sc(Fv)2 contained in this plasmid pCHOhuM1scDb are shown in SEQ ID [[NØ:]] **NOS: 79 and 114, respectively.**